Clinical Trials Logo

Clinical Trial Summary

This study is to measure prevalence of established and candidate molecular markers of drug resistant malaria at Komé, Doba, Republic of Chad.


Clinical Trial Description

This is a cross-sectional, observational study using dried blood samples collected from P. falciparum-infected individuals at the time of malaria diagnosis to measure the prevalence of known and candidate molecular markers of resistance to artemisinin and non-artemisinin ACT partner drugs. A maximum of 200 participants will be enrolled at each participating site per year. Study duration is 2 years. Therefore total participant is up to 400.

Prospective participants will have blood collected for dried blood spot (DBS) study sample after providing informed consent. Individuals with confirmed P. falciparum infection will have DBS samples included for molecular analyses for known and candidate molecular markers of antimalarial drug resistance. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02895568
Study type Observational
Source University of Oxford
Contact Mehul Dhorda, PhD
Email mehul.dhorda@wwarn.org
Status Recruiting
Phase N/A
Start date October 2016
Completion date December 2018

See also
  Status Clinical Trial Phase
Completed NCT01935882 - Low Dose Primaquine for Clearance of Gametocytes Phase 2/Phase 3
Completed NCT01728701 - Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis Phase 1
Completed NCT01775592 - Plasmodium Falciparum Artemisinin Resistance Vietnam Phase 4
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Recruiting NCT03384498 - Malaria Genetic Surveillance N/A
Completed NCT02259426 - Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission Phase 3
Completed NCT01465048 - Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe N/A
Active, not recruiting NCT00392015 - NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1 Phase 1/Phase 2
Active, not recruiting NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Completed NCT00295581 - PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria Phase 1
Recruiting NCT01322581 - A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali
Completed NCT02418962 - Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults Phase 1
Not yet recruiting NCT03452475 - Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children Phase 3
Completed NCT01160562 - Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
Completed NCT03132402 - ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
Recruiting NCT03172221 - Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women N/A
Not yet recruiting NCT03219281 - Prevalence Survey of Antimalarial Drug Resistance Markers at Sites in India N/A
Completed NCT02090036 - Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes Phase 4
Completed NCT00197054 - A Study to Evaluate Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya. Phase 2
Completed NCT01930331 - Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Phase 4